Introduction {#s1}
============

In the 1920s, Otto Warburg first discovered that cancer cells vigorously take up glucose and preferentially produce lactate even in the presence of oxygen, a phenomenon now widely termed the Warburg effect or aerobic glycolysis ([@bib66]). Despite his pioneering work, the Warburg effect was largely disregarded for the subsequent decades ([@bib36]; [@bib31]). After the discoveries of oncogenes and tumor suppressor genes, cancers are generally considered as genetic diseases rather than metabolic ones ([@bib69]; [@bib53]). Not until the 1980s did the revisiting of the Warburg effect in connection with oncogenes spark substantial research in cancer metabolism ([@bib31]), laying the foundation for 2-deoxy-2-(^18^F)fluoro-D-glucose (^18^F-FDG) positron emission tomography (PET) in clinical cancer diagnosis ([@bib62]; [@bib2]), recognition of metabolic reprogramming as a hallmark of cancer ([@bib24]; [@bib68]) and development of anti-cancer agents targeting aerobic glycolysis ([@bib20]; [@bib46]; [@bib23]).

How the Warburg effect arises and contributes to tumor progression have always been the center in the field of cancer metabolism ([@bib37]). Warburg hypothesized that mitochondrial impairment is the cause of aerobic glycolysis and cancer ([@bib67]), which has sparked much controversy among scientists ([@bib52]). Contrary to his idea, the current, widely-accepted view is that oncogenic drivers such as RAS, MYC, hypoxia-inducible factors (HIFs) and steroid receptor coactivators (SRCs) promote cancer cell proliferation and directly stimulate aerobic glycolysis through regulating transcriptional expression or catalytic activities of metabolic enzymes ([@bib31]). Several explanations for the Warburg effect have been put forward, including rapid adenosine triphosphate (ATP) production and de novo biosynthesis of macromolecules ([@bib36]). Recently, Warburg effect functions are being re-evaluated as a growing body of evidence shows that metabolic rewiring in cancers impacts cell signaling and epigenetics ([@bib36]; [@bib38]).

*Drosophila* has proven to be a powerful genetic model organism for studying tumorigenesis in vivo largely due to high conservation of genes and signaling cascades between human and flies and reduced genetic redundancy ([@bib22]; [@bib28]) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). In a recent study, we showed that elevation of *Drosophila* Hipk causes an in vivo tumor model characterized by tissue overgrowth, loss of epithelial integrity and invasion-like behaviors ([@bib4]). The tumorigenic roles of *Drosophila* Hipk seem to be conserved in mammals as the four members of the HIPK family (HIPK1-4) are also implicated in certain cancers (Reviewed in [@bib5]). For example, HIPK1 is highly expressed in breast cancer cell lines, colorectal cancer samples and oncogenically-transformed mouse embryo fibroblasts ([@bib30]; [@bib50]). Also, HIPK2 is elevated in certain cancers including cervical cancers, pilocytic astrocytomas, colorectal cancer cells and in other proliferative diseases, such as thyroid follicular hyperplasia ([@bib1]; [@bib9]; [@bib71]; [@bib10]; [@bib51]; [@bib13]; [@bib32]). To gain a better understanding of cancer metabolism, we set out to use the fly Hipk tumor model to investigate whether and how cellular metabolism is altered in tumor cells. We find that Hipk-induced tumorous growth is accompanied by elevated aerobic glycolysis. Furthermore, we identify novel feedback mechanisms leading to prolonged dMyc expression and hence tumorigenesis. Our study reveals potential metabolic vulnerabilities that could be exploited to suppress tumor growth.

Results {#s2}
=======

Hipk tumor cells exhibit elevated glucose uptake and consumption {#s2-1}
----------------------------------------------------------------

Larval imaginal epithelia such as wing and eye-antennal imaginal discs, which give rise to wing and eye structures in adult flies, respectively, are extensively used as tumor models to study human carcinomas ([@bib27]). To generate the Hipk tumor model, we used the Gal4-UAS system ([@bib6]) to induce overexpression of *hipk* in larval wing discs (full genotype: *dpp-Gal4\>UAS-RFP + UAS-hipk*, abbreviated as *dpp\>RFP + hipk*) ([Figure 1c--d](#fig1){ref-type="fig"}). Fluorescent proteins, for example red fluorescent proteins (RFP) or green fluorescent proteins (GFP), were co-expressed to label the transgene-expressing cells. As previously reported ([@bib4]), in contrast to control discs (*dpp\>RFP*) ([Figure 1a--b](#fig1){ref-type="fig"}), tumorous growth and severe tissue distortions were evident in *hipk-*expressing discs (*dpp\>RFP +  hipk*) ([Figure 1c--d](#fig1){ref-type="fig"}).

![Hipk tumor cells exhibit elevated glucose uptake and reduced intracellular glucose levels.\
(**a--d**) Incorporation of 2-NBDG (green) in control (*dpp\>RFP*) (**a, b**) and *hipk-*expressing (*dpp\>RFP +  hipk*) wing discs (**c, d**). Insets (dashed line) in (**a** and **c**) are magnified in (**b** and **d**), respectively. RFP (red) marks the transgene-expressing cells. F-actin (gray) staining shows the overall tissue morphology. (**e--h**) Intracellular glucose FRET efficiency (FRET/CFP) (colored using Fire Lookup Table) in control (*dpp\>Glucose Sensor*) (**e--f**) and *hipk*-expressing (*dpp\>Glucose Sensor+hipk*) wing discs (**g--h**). Individual CFP and FRET channels are shown in cyan and yellow, respectively. Insets (dashed line) in (**e** and **g**) are magnified in (**f** and **h**), respectively. Insets (solid line) at the upper right corners in (**e--e''**) and (**g--g''**) show the corresponding signals at single pixel level. (**i**) Quantification of mean 2-NBDG intensity in *hipk-*expressing cells (RFP positive) and the neighboring wild-type cells (RFP negative) in *hipk*-expressing wing discs (*dpp \>RFP +  hipk*) (*n* = 12 wing discs). (**j**) Chemical structures of D-glucose (top) and 2-NBDG (bottom). (**k**) Quantification of glucose FRET efficiency in control (*dpp\>Glucose Sensor*) and *hipk-*expressing (*dpp \>Glucose Sensor + hipk*) wing discs (*n* = 11 wing discs per genotype). (**l**) Schematic diagram of the FRET-based glucose sensor. Glucose binding induces conformational changes of glucose-binding domain (GBD) such that FRET occurs and YFP emission increases. Scale bars, 50 μm. Exact *p* values are shown and calculated using unpaired two-tailed *t-*test.\
10.7554/eLife.46315.006Figure 1---source data 1.Analyses of glucose metabolism in Hipk tumor cells and evaluation of RNAi tools.](elife-46315-fig1){#fig1}

To ask if elevated Hipk alters cellular metabolism, we first used a fluorescently labeled glucose analog, 2-deoxy-2-\[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino\]-D-glucose (2-NBDG) ([Figure 1j](#fig1){ref-type="fig"}). Like D-glucose, 2-NBDG is transported into cells through glucose transporters and phosphorylated by hexokinases ([@bib70]; [@bib45]). However, due to the presence of the fluorescent amino group at the C-2 position, 2-NBDG-6-phosphate cannot proceed further through glycolysis and is consequently trapped within the cells, rendering it a probe for monitoring glucose uptake ([@bib45]). 2-NBDG is often used in *Drosophila* to measure glucose uptake. For example, overexpression of *glut1* (encoding Glucose transporter 1) is sufficient to promote the accumulation in 2-NBDG ([@bib43]). Increased import of 2-NBDG is also found in *dMyc*-expressing cells ([@bib12]) and *Ras^V12^scrib^−/−^* tumor cells ([@bib29]), indicating that such cells acquire enhanced glucose metabolism.

Similarly, we found that cells with elevated Hipk (RFP positive) in *hipk*-expressing wing discs (*dpp\>RFP +  hipk*) exhibited statistically significant 2-NBDG accumulation when compared with the neighboring wild-type cells (RFP negative) ([Figure 1c--d and i](#fig1){ref-type="fig"}) or cells (either RFP positive or negative) in control discs (*dpp\>RFP*) ([Figure 1a--b](#fig1){ref-type="fig"}). A comparable phenomenon was seen in larval eye-antennal discs ([Figure 1---figure supplement 1a--b](#fig1s1){ref-type="fig"}). Furthermore, we detected a mild upregulation of *glut1* (1.6-fold) in *hipk-*expressing discs by quantitative real-time PCR (qRT-PCR) ([Figure 2a](#fig2){ref-type="fig"}). Knockdown of *glut1* using RNA interference (RNAi) moderately reduced 2-NBDG incorporation in Hipk tumor cells ([Figure 1---figure supplement 1c--d](#fig1s1){ref-type="fig"}). The knockdown efficiency of *glut1-RNAi* was tested using a ubiquitous Gal4 driver, *act5c-Gal4* ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}). Together, these results suggest that elevated Hipk facilitates the import of glucose into cells at least in part through augmenting Glut1 expression.

![Elevated Hipk induces robust expression of a subset of glycolytic genes.\
(**a, b**) qRT-PCR analysis of glycolytic gene expression in *hipk-*expressing discs (*dpp\>hipk*) relative to control discs (*dpp\>GFP*) (**a**). Data are mean ± sem. *n* = 3 independent experiments with samples pooled from 10 to 20 wing discs per genotype. Schematic diagram of glycolysis (**b**). Fold changes are shown in brackets. Glycolytic enzymes with more than 1.5-fold transcriptional upregulation in *hipk-*expressing discs are marked in red. Bi- and uni-directional arrows indicate the reversible and essentially irreversible steps in glycolysis, respectively. Dashed arrow (blue) shows the positive allosteric regulation of Pfk by fructose-2,6-BP. Full names of the glycolytic genes are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Exact *p* values are shown and calculated using unpaired two-tailed *t-*test. (**c--d**) Expression of *Ldh-GFP* (green), an enhancer trap to monitor *Ldh* expression, in control (genotype: *Ldh-GFP/+*) (**c**) and *hipk-*expressing wing discs (genotype: *Ldh-GFP/dpp\>hipk*) (**d**). DAPI staining for DNA (blue) reveals tissue morphology. White arrowhead in **d''** indicates marked induction of *Ldh* expression. Scale bars, 50 μm.\
10.7554/eLife.46315.008Figure 2---source data 1.Expression profile of glycolytic genes in*hipk*-expressing discs.](elife-46315-fig2){#fig2}

Next, we evaluated the intracellular glucose levels using a FRET (Förster resonance energy transfer)-based glucose sensor, which is composed of a glucose-binding domain (GBD) fused with cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) ([@bib64]; [@bib18]) ([Figure 1l](#fig1){ref-type="fig"}). The binding of glucose to GBD induces conformational changes, leading to increased FRET efficiency (the ratio of FRET to CFP). Intriguingly, a lower FRET/CFP ratio indicative of reduced glucose concentration was observed in *hipk-*expressing cells ([Figure 1g--h and k](#fig1){ref-type="fig"}) when compared with control discs ([Figure 1e--f and k](#fig1){ref-type="fig"}). This implies that despite enhanced glucose uptake, glucose is substantially utilized in the rapidly proliferating Hipk tumor cells.

Elevated Hipk induces robust expression of a subset of glycolytic genes {#s2-2}
-----------------------------------------------------------------------

Glycolysis is a catabolic process that breaks down glucose into pyruvate via multiple enzymatic steps. To ask if glycolysis is upregulated, we examined the expression profile of glycolytic genes by qRT-PCR and changes greater than 1.5-fold were considered significant. We isolated RNA from whole wing discs expressing either GFP (control) or *hipk* under the *dpp-Gal4* driver control. qRT-PCR analyses revealed that genes encoding Hexokinases (Hex-A and Hex-C, 2.2-fold and 4.3-fold respectively), Phosphoglucose isomerase (Pgi, 2.4-fold), Phosphofructokinase 2 (Pfk2, also known as Pfrx, 2.7-fold) and Lactate dehydrogenase (Ldh, also known as Impl3, 3.4-fold) are significantly upregulated in *hipk-*expressing discs ([Figure 2a--b](#fig2){ref-type="fig"}). Expression of other glycolytic genes, on the other hand, remained relatively unchanged.

As the Dpp domain comprises 10--20% of the wing disc, the glycolytic gene upregulation within *hipk*-expressing cells is likely understated. In light of such a limitation, we used a GFP-based enhancer trap to monitor *Ldh* transcription in vivo (*Ldh-GFP*) ([@bib48]). In control wing discs, little *Ldh-GFP* was detected ([Figure 2c](#fig2){ref-type="fig"}), indicating that *Ldh* is minimally expressed under physiological conditions as previously described ([@bib65]). On the contrary, we observed robust *Ldh-GFP* expression in *hipk*-expressing wing discs ([Figure 2d](#fig2){ref-type="fig"}), confirming that elevated Hipk induces *Ldh* expression.

Hexokinases phosphorylate glucose to form glucose-6-phosphate (G6P), which is the first essentially irreversible step in glycolysis ([Figure 2b](#fig2){ref-type="fig"}). Pgi catalyzes the reversible conversion of G6P and fructose-6-phosphate. Pfk2 is a bifunctional enzyme that synthesizes fructose-2,6-bisphosphate (F2,6-BP). F2,6-BP is a potent allosteric activator of Pfk, which governs the committed, second irreversible step in glycolysis. Ldh, similar to LDHA in vertebrates ([@bib49]), favors the reduction of pyruvate to lactate, regenerating nicotinamide adenine dinucleotide (NAD^+^) such that glycolysis continues unabated ([@bib61]). The robust upregulation of these glycolytic enzymes in *hipk*-expressing discs is in agreement with previous data implying that glucose consumption is stimulated. Taken together, the results support the hypothesis that Hipk tumor cells exhibited elevated glycolytic activities, resembling the Warburg effect seen in cancers.

Elevated Hipk drives dMyc upregulation in a region-specific manner {#s2-3}
------------------------------------------------------------------

To elucidate the underlying mechanisms for the metabolic alterations in the Hipk tumors, we examined gene expression of dMyc and Sima (HIF1-α in vertebrates) since these two transcription factors are well-known inducers of glycolysis in cancer cells ([@bib40]; [@bib39]). qRT-PCR analyses showed that *dMyc* was upregulated in *hipk-*expressing discs whereas *sima* expression remained unchanged ([Figure 3a](#fig3){ref-type="fig"}).

![Elevated Hipk drives dMyc upregulation in a region-specific manner.\
(**a**) qRT-PCR analysis of *dMyc* and *sima* expression in *hipk-*expressing discs (*dpp\>hipk*) relative to control discs (*dpp\>GFP*). Data are mean ± sem. *n* = 3 independent experiments with samples pooled from 10 to 20 wing discs per genotype. Exact *p* values are shown and calculated using unpaired two-tailed *t-*test. (**b**) Schematic diagram of a larval wing imaginal disc, with notum, hinge and pouch in light gray, dark gray and white, respectively. (**c--d**) β-galactosidase staining (red) in control (*dpp\>GFP*) (**c**) and *hipk-*expressing (*dpp\>GFP +  hipk*) (**d**) wing discs harboring a *lacZ* reporter to monitor the transcriptional induction of dMyc (*dMyc-lacZ*). White arrowhead in (**d'**) indicates robust upregulation of *dMyc* in the wing hinge. (**e--f**) dMyc staining (gray) in control (*dpp\>GFP*) (**e**) and *hipk-*expressing (*dpp\>GFP +  hipk*) (**f**) wing discs. White arrowhead in (**f'**) indicates dMyc accumulation in the wing hinge. GFP (green) marks the transgene-expressing cells. Scale bars, 50 μm.\
10.7554/eLife.46315.010Figure 3---source data 1.Expression levels of*dMyc*and*sima*in*hipk*-expressing discs.](elife-46315-fig3){#fig3}

Larval wing discs are mainly composed of three regions known as the notum, hinge and pouch, corresponding to the adult structures they give rise to ([Figure 3b](#fig3){ref-type="fig"}). Using a *dMyc-lacZ* enhancer trap (encoding β-galactosidase (β-gal)) to monitor the transcriptional control of *dMyc* in vivo, we observed that *dMyc* was expressed at high levels in the pouch region of control discs ([Figure 3c](#fig3){ref-type="fig"}). In the hinge and notum areas of control discs, *dMyc* was minimally and weakly expressed, respectively ([Figure 3c](#fig3){ref-type="fig"}). In *hipk-*expressing discs, we found intense β-galactosidase staining, confirming that Hipk cell-autonomously drives transcriptional upregulation of dMyc. Interestingly, the increase in the β-gal signal intensity appeared to be the largest in the wing hinge ([Figure 3d](#fig3){ref-type="fig"}, arrowhead) where the tumor cells proliferated most rapidly, while the intensity faded when moving away from the hinge region ([Figure 3d](#fig3){ref-type="fig"}).

Immunofluorescent staining using antibodies against dMyc confirmed the accumulation of dMyc proteins in Hipk tumor cells especially in the wing hinge ([Figure 3e--f](#fig3){ref-type="fig"}), which positively correlates with the marked increase in *dMyc* mRNA levels in the same region ([Figure 3d](#fig3){ref-type="fig"}). dMyc proteins appeared to not accumulate in *hipk*-expressing cells in the wing pouch ([Figure 3f](#fig3){ref-type="fig"}), possibly due to weak induction in dMyc transcription ([Figure 3d](#fig3){ref-type="fig"}).

The variability in Hipk-induced dMyc accumulation suggests a potential region-specificity in dMyc upregulation. To assess this, we generated random flip-out clones of *hipk*-expressing cells. The clones were marked by RFP. We observed that *hipk-*expressing clones located in the dorsal hinge ([Figure 4c](#fig4){ref-type="fig"}, arrowhead, [Figure 4---figure supplement 1a](#fig4s1){ref-type="fig"}), the lateral hinge ([Figure 4---figure supplement 1b](#fig4s1){ref-type="fig"}) as well as the epithelium on the peripodial side exhibited marked dMyc accumulation ([Figure 4---figure supplement 1c](#fig4s1){ref-type="fig"}). On the contrary, when *hipk-*expressing clones were located in the wing pouch, dMyc levels appeared unchanged ([Figure 4---figure supplement 1d](#fig4s1){ref-type="fig"}). Altogether, our data imply that elevated Hipk drives dMyc upregulation in a region-specific manner.

![Elevated Hipk and perturbations in cell signaling cascades induce dMyc accumulation in the wing hinge region.\
(**a**) dMyc staining (gray) in a control wing disc. (**b**) Schematic diagram of a larval wing imaginal disc. The hinge region can be divided into dorsal, lateral and ventral compartments. (**c--g**) dMyc staining (gray) in flip-out clones expressing *hipk* (**c**), *yki-S168A* (**d**), *Arm-S10* (**e**), *Ci* (**f**) or *N-act* (**g**) under the control of *actin-Gal4*. RFP (red) marks the transgene-expressing clones. DAPI staining for DNA (blue) reveals tissue morphology. (**c', c''-g', g''**) are magnified images of the insets (dashed lines) in (**c-g**). (**c**) White arrowhead indicates dMyc accumulation in a *hipk-*expressing clone. (**d**) White arrowheads indicate *yki-S168A-*expressing clones with dMyc accumulation. (**e**) White arrowheads indicate ectopic dMyc expression at the boundary of the *Arm-S10*-expressing clone and the neighboring wild-type cells. (**f**) White arrowheads indicate dMyc upregulation in *Ci-*expressing clones. (**g**) White arrowheads indicate dMyc accumulation in *N-act-*expressing clones and the adjacent wild-type cells. Scale bars, 50 μm.](elife-46315-fig4){#fig4}

Elevated Hipk modulates dMyc expression likely through convergence of multiple perturbed signaling cascades {#s2-4}
-----------------------------------------------------------------------------------------------------------

We further investigated the molecular mechanisms underlying the upregulation of dMyc in Hipk tumor cells. Earlier studies have demonstrated that Hipk is a versatile regulator of numerous signaling pathways. For example, Hipk stimulates the transcriptional activity of Yorkie (Yki, a *Drosophila* orthologue of YAP/TAZ), the effector of the Hippo tumor suppressor pathway ([@bib8]; [@bib47]). Hipk also functions as a positive regulator of both Wnt/Wingless (Wg) and Hedgehog signaling by stabilizing Armadillo (β-catenin in vertebrates) and Cubitus interruptus (Ci; Gli in vertebrates), respectively ([@bib33]; [@bib56]). In addition, Hipk has been found to antagonize Groucho, a global co-repressor, to promote Notch signal transduction ([@bib34]). If Hipk-induced dMyc upregulation is through deregulation of multiple signaling pathways, we would expect to see dMyc accumulation when the signaling pathways are perturbed. We first focused on the dorsal hinge area since ectopic dMyc expression and tumor growth are most striking in such region in *hipk-*expressing discs.

Flip-out clones expressing a constitutively active form of Yki (Yki-S168A) to inactivate the Hippo pathway were usually round and most of them in the dorsal hinge displayed dMyc upregulation ([Figure 4d](#fig4){ref-type="fig"}, arrowheads). Wing discs with flip-out clones expressing an active form of Arm (Arm-S10) featured an expansion in the hinge area and some dMyc accumulated at the interface between the clone and the neighboring wild-type cells ([Figure 4e](#fig4){ref-type="fig"}, arrowheads) but not at the center of the clone. Flip-out clones expressing Ci to activate Hedgehog signaling in the hinge region were round or irregular in shape and exhibited elevated levels of dMyc ([Figure 4f](#fig4){ref-type="fig"}, arrowheads). Consistent with previous findings ([@bib14]), expression of activated Notch appeared to induce dMyc accumulation in both cell and non-cell autonomous fashions in the hinge area likely involving a signaling relay ([Figure 4g](#fig4){ref-type="fig"}). Therefore, individual perturbation of signaling pathways that have been previously shown to be regulated by Hipk was sufficient to trigger ectopic dMyc expression in the hinge region.

In the wing pouch region, activation of Yki failed to cause any dMyc upregulation ([Figure 4---figure supplement 1e](#fig4s1){ref-type="fig"}). This is in contrast to previous findings that overexpression of Yki increased dMyc protein levels in both hinge and pouch regions ([@bib72]). Such discrepancy could be due to the different expression levels of the *UAS-Yki* constructs. Flip-out clones expressing Arm-S10 or activated Notch displayed reduced dMyc expression ([Figure 4---figure supplement 1f and h](#fig4s1){ref-type="fig"}), which is consistent with earlier studies showing that Wg and Notch signaling negatively regulate dMyc expression in the pouch region ([@bib15]; [@bib26]). Clones with *Ci* overexpression were few and tiny in the wing pouch and the dMyc levels in the clones seemed comparable to those in the neighboring wild-type cells ([Figure 4---figure supplement 1g](#fig4s1){ref-type="fig"}). Our data suggest that the region specificity in dMyc upregulation applies to not only Hipk tumor cells, but also cells with other tumorigenic stimuli.

In summary, our data show that in the wing hinge region where Hipk tumor growth is most prominent, dMyc protein markedly accumulates. Individual perturbations in signaling pathways that have been shown to be regulated by Hipk also result in ectopic dMyc expression in the same region. Hence, it is likely that in the rapidly proliferating Hipk tumor cells, aberrant signals propagate and converge at the transcriptional control of dMyc. In other words, the modulation of dMyc levels by Hipk seems to be a cumulative effect of alterations in multiple signaling outputs.

Hipk-induced dMyc governs aerobic glycolysis and tumor growth {#s2-5}
-------------------------------------------------------------

In addition to growth control, dMyc/MYC plays a conserved role in upregulating glycolysis in vertebrates and *Drosophila* during normal development and in cancers ([@bib12]; [@bib19]). As expected and previously reported ([@bib12]), overexpression of *dMyc* caused marked 2-NBDG uptake ([Figure 5a and d](#fig5){ref-type="fig"}) and promoted glycolytic gene expression ([Figure 5e](#fig5){ref-type="fig"}). More importantly, knockdown of *dMyc* by RNAi in *hipk*-expressing discs reversed the 2-NBDG accumulation ([Figure 5b--d](#fig5){ref-type="fig"}) and moderately suppressed glycolytic gene upregulation ([Figure 5e](#fig5){ref-type="fig"}), suggesting that dMyc is essential for the enhanced glycolysis in Hipk tumor cells. Additionally, knockdown of *dMyc* significantly suppressed the tumorous growth and tissue distortions in *hipk-*expressing discs, as seen by the decrease in GFP positive cells ([Figure 5f--g](#fig5){ref-type="fig"}). Using an independent RNAi construct targeting *dMyc* (*dMyc-RNAi \#2*), we observed a similar effect upon silencing of *dMyc* ([Figure 5h](#fig5){ref-type="fig"}). dMyc immunofluorescent staining showed the efficient knockdown when *dMyc-RNAi* constructs were expressed ([Figure 5g--i](#fig5){ref-type="fig"}). Wing discs with *dMyc* knockdown alone appeared wild-type ([Figure 5i](#fig5){ref-type="fig"}). Altogether, our results imply that dMyc-induced glycolysis may be a key driver for Hipk tumor growth. Intriguingly, overexpression of *dMyc* alone ([Figure 5a](#fig5){ref-type="fig"}), despite the enhanced glycolysis, failed to reproduce the tumorous phenotypes observed in *hipk-*expressing discs ([Figure 5f](#fig5){ref-type="fig"}). Thus, while upregulation of dMyc is indispensable for Hipk-induced glycolysis and tumor growth, additional mechanisms are involved in the Hipk tumors to trigger the tumorigenic process.

![dMyc mediates the Hipk-induced glycolysis and tumor growth.\
(**a--c**) Incorporation of 2-NBDG (green) in *dMyc*-expressing wing disc (*dpp\>dMyc*) (**a**), *hipk*-expressing wing disc (*dpp\>RFP +  hipk*) (**b**), and *hipk*-expressing wing disc with *dMyc* knockdown (*dpp\>RFP + hipk + dMyc-RNAi*) (**c**). Insets (dashed line) in (**a**, **b** and **c**) are magnified in (**a'--a''**), (**b'--b''**) and (**c'--c''**), respectively. dMyc staining (gray) in (**a**) marks the *dMyc-*overexpressing cells. RFP (red) in (**b** and **c**) marks the transgene-expressing cells. (**d**) Quantification of mean 2-NBDG intensity in *dMyc-*expressing cells and the neighboring wild-type cells in *dMyc*-expressing wing discs (*dpp\>dMyc*) (left), in *hipk-*expressing cells (RFP positive) and the neighboring wild-type cells (RFP negative) in *hipk*-expressing discs (*dpp\>RFP +  hipk*) (middle) and, in *hipk, dMyc-RNAi* co-expressing cells (RFP positive) and the neighboring wild-type cells (RFP negative) in *hipk*-expressing discs with *dMyc* knockdown (*dpp\>RFP + hipk + dMyc-RNAi*) (right). *n* = 6 discs per genotype. (**e**) qRT-PCR analysis of expression of a set of glycolytic genes in *hipk-*expressing wing discs (*dpp\>hipk*), *hipk-*expressing discs with *dMyc* knockdown (*dpp\>hipk +  dMyc-RNAi*), and *dMyc-*expressing discs relative to control discs (*dpp\>GFP*). Data are mean ± sem. *n* = 3 independent experiments with samples pooled from 10 to 20 wing discs per genotype. (**f--i**) dMyc staining (gray in **f''**), (**g'', h'' and i''**) in *hipk-*expressing disc (*dpp\>GFP +  hipk*) (**f**), *hipk* and *dMyc-RNAi* co-expressing disc (*dpp\>GFP + hipk + dMyc-RNAi*) (**g**), *hipk* and *dMyc-RNAi \#2* co-expressing disc (*dpp\>GFP + hipk + dMyc-RNAi \#2*) (**h**) and *dMyc* knockdown disc (*dpp\>GFP +  dMyc-RNAi*) (**i**). GFP (green) marks the transgene-expressing cells. DAPI staining for DNA (blue) reveals tissue morphology. Scale bars, 50 μm. Exact *p* values are shown and calculated using unpaired two-tailed *t-*test.\
10.7554/eLife.46315.014Figure 5---source data 1.Analyses of glucose metabolism in*hipk*-expressing discs upon*dMyc*knockdown.](elife-46315-fig5){#fig5}

Aerobic glycolysis (the Warburg effect) is essential to tumor growth through sustaining ectopic dMyc expression {#s2-6}
---------------------------------------------------------------------------------------------------------------

Earlier studies have shown that flies incompetent at glycolysis displayed reduced viability as deletion or ubiquitous knockdown of the glycolytic genes *pfk*, *ald*, *pgk*, *pglym78*, *eno* or *pyk* resulted in lethality ([@bib63]; [@bib21]; [@bib41]; [@bib58]). Likewise, we observed that flies ubiquitously depleted of *pgk* (*act5c\>pgk-RNAi*) failed to reach the larval stage. Flies lacking *pfk* (*act5c\>pfk-RNAi*) or *pyk* (*act5c\>pyk-RNAi*) reached the larval stage but could not pupariate. Flies with *pfk2* knockdown (*act5c\>pfk2-RNAi*) died at the early pupal stage but did not differentiate further to become late pupae. Most flies lacking *glut1* (*act5c\>glut1*-*RNAi*) or *pgi* (*act5c\>pgi*-*RNAi*) succeeded in emerging as adults. The timing of lethality following knockdown targeting glycolytic genes could presumably be influenced by maternal contribution, knockdown efficiency or the importance of the glycolytic step which the particular enzyme controls. To confirm the regulatory roles of Pfk and Pfk2 in glycolytic flux, we measured the relative pyruvate content in the knockdown larvae. Consistent with previous work ([@bib35]), knockdown of *pfk* significantly decreased pyruvate levels ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Similarly, knockdown of *pfk2* induced an approximately 60% drop in the pyruvate content ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The knockdown efficiencies of all RNAi constructs used in this study to silence glycolytic genes were evaluated by qRT-PCR analyses ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

To examine the roles of glycolytic activation in Hipk tumor cells, we used RNAi to deplete key glycolytic genes. Knockdown of *hex-A* or *hex-C* had negligible effects on Hipk tumor growth; as did *hex-A* and *hex-C* double knockdown ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Similarly, knockdown of *glut1* or *pgi* failed to block Hipk-induced tumorigenesis ([Figure 6---figure supplement 3a--b](#fig6s3){ref-type="fig"}). Knockdown of *pfk2*, on the contrary, markedly prevented tumor growth and restored tissue architecture in *hipk-*expressing discs ([Figure 6b](#fig6){ref-type="fig"}), suggesting that the committed step of glycolysis determines Hipk tumorigenesis. Indeed, the effect of *pfk* knockdown was comparable to that of *pfk2* knockdown ([Figure 6c](#fig6){ref-type="fig"}), even though we did not detect significant *pfk* upregulation (\<1.5 fold) in *hipk-*expressing discs ([Figure 2a](#fig2){ref-type="fig"}). Knockdown of *pgk, pyk* or *Ldh* appeared to slightly restrict Hipk tumor growth but the tissue morphology remained distorted ([Figure 6d](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3c--d](#fig6s3){ref-type="fig"}).

![Pfk2 and Pfk sustain Hipk tumor growth through post-transcriptional regulation of dMyc.\
(**a--d**) dMyc staining (gray in **a''**, **b'', c'' and d''**) in *hipk-*expressing wing disc (*dpp\>GFP +  hipk*) (**a**), *hipk* and *pfk2-RNAi* co-expressing disc (*dpp\>GFP + hipk + pfk2-RNAi*) (**b**), *hipk* and *pfk-RNAi* co-expressing disc (*dpp\>GFP + hipk + pfk-RNAi*) (**c**) and *hipk* and *Ldh-RNAi* co-expressing disc (*dpp\>GFP + hipk + Ldh-RNAi*) (**d**). GFP (green) marks the transgene-expressing cells. DAPI staining for DNA (blue) reveals tissue morphology. (**e--g**) Hipk staining (magenta in **e**, **f and g**) and β-galactosidase staining (red in **e'**, **f' and g'**) in *hipk-*expressing disc (*dpp\>hipk*) (**e**), *hipk* and *pfk2-RNAi* co-expressing disc (*dpp\>hipk + pfk2-RNAi*) (**f**), *hipk* and *pfk-RNAi* co-expressing disc (*dpp\>hipk +  pfk-RNAi*) (**g**). All wing discs harbor a *lacZ* reporter to monitor the transcriptional induction of *dMyc* (*dMyc-lacZ*). Scale bars, 50 μm.\
10.7554/eLife.46315.021Figure 6---source data 1.Data for pyruvate measurements.](elife-46315-fig6){#fig6}

We also examined dMyc expression in Hipk tumor cells when glycolysis was inhibited. Intriguingly, dMyc accumulation was largely abolished in *hipk-*expressing discs when *pfk2* or *pfk* was knocked down ([Figure 6a--c](#fig6){ref-type="fig"}). In the absence of *hipk* overexpression, neither knockdown of *pfk* nor *pfk2* affected the normal dMyc expression pattern nor led to defects in tissue growth ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). Knockdown of *glut1*, *pgi*, *pgk*, *pyk* or *Ldh* in Hipk tumor cells did not rescue dMyc upregulation ([Figure 6d](#fig6){ref-type="fig"}, [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Together, our results suggest that dMyc accumulation and the associated Hipk tumor growth are most sensitive to the committed step of glycolysis governed by Pfk2-Pfk.

Using the *dMyc-lacZ* reporter, we found that *dMyc* transcriptional activation remained robust when *pfk2* or *pfk* was depleted in Hipk tumor cells even though the tumor growth was reduced and dMyc protein levels were reduced ([Figure 6e--g](#fig6){ref-type="fig"}). Thus, our data indicate that Pfk2 and Pfk are required to sustain ectopic dMyc expression specifically in Hipk tumor cells through post-transcriptional regulation.

The control of Hipk tumor growth by Pfk2 or Pfk seemed not to be a consequence of altered Hipk protein stability or functions because of the following reasons. First, we did not detect a noticeable change in Hipk protein levels in discs depleted of *pfk2* or *pfk* when compared with discs expressing *hipk* alone ([Figure 6e--g](#fig6){ref-type="fig"}), indicating that blocking glycolysis does not trigger Hipk protein degradation. Second, the robust stimulation of the *dMyc-lacZ* reporter in *hipk*-expressing discs with *pfk2* or *pfk* knockdown suggests that Hipk activities remain intact. Indeed, when we examined other signaling targets downstream of Hipk as readouts for Hipk activity, we found that Hipk-mediated stabilization of Armadillo (Wnt/Wg signaling), and induction of Cyclin E or *expanded-lacZ* (Hippo signaling) remained unaffected by knockdown of *pfk2* or *pfk* in a Hipk overexpression background, indicating Hipk is still functional ([Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}).

Altogether, our data suggest that while dMyc upregulation promotes glycolytic activities, the upregulation of Pfk2, along with subsequent F2,6-BP biosynthesis and Pfk activation, is required to foster the accumulation of dMyc proteins. In other words, a positive feedback loop between dMyc and aerobic glycolysis is formed, coordinating growth signals with metabolic states to reinforce tumor progression.

Discussion {#s3}
==========

dMyc-driven aerobic glycolysis in a hipk tumor model {#s3-1}
----------------------------------------------------

Multiple approaches and tools have been developed to measure glycolysis including measurement of the extracellular acidification rate (ECAR), fluorescent probes, biosensors, fluorescent/colorimetric assays and mass spectrometry ([@bib3]; [@bib60]; [@bib59]). In the Hipk tumor model, the tumor cells are surrounded by wild-type cells. Our study primarily used fluorescence imaging such that we could examine changes in metabolite levels, gene and protein expression between tumor cells and the adjacent wild-type cells. Our work delineates the causes and significance of metabolic changes in tumor cells.

*Drosophila* tumor models frequently acquire metabolic changes, especially the Warburg effect. For instance, epidermal growth factor receptor (EGFR)-driven tumors, tumors with activated platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) receptor (Pvr) and tumors with polarity loss (such as *scrib* or *dlg* mutant tumors) feature robust upregulation of *Ldh* among other glycolytic genes ([@bib65]; [@bib16]; [@bib7]). Depletion of *Ldh* was shown to reduce growth of EGFR-driven tumors but not tumors with polarity loss ([@bib16]; [@bib7]). In *Ras^V12^scrib^−/−^* tumors, elevated glucose uptake was evident, but its significance was not evaluated ([@bib29]). Similar to the previously described models, Hipk tumor cells exhibited elevated glucose metabolism ([Figures 1](#fig1){ref-type="fig"}--[2](#fig2){ref-type="fig"}). Metabolic reprogramming was driven by dMyc upregulation ([Figures 3](#fig3){ref-type="fig"}--[5](#fig5){ref-type="fig"}). Although the transcript levels of another glycolytic inducer *sima* remained unchanged ([Figure 3a](#fig3){ref-type="fig"}), we could not eliminate the possibility that Sima protein levels are altered in the tumor cells. Thus, whether Sima is involved in the tumor growth warrants further studies. Genetical inhibition of Pfk or Pfk2 was sufficient to block Hipk-induced tumorigenesis whereas depletion of Pgk, Pyk or Ldh at most slightly reduced tumor growth ([Figure 6](#fig6){ref-type="fig"}; [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Therefore, our data suggest that targeted but not generic inhibition of glycolysis is required to abrogate tumor growth.

A feedback loop between dMyc and aerobic glycolysis as a metabolic vulnerability in tumor cells {#s3-2}
-----------------------------------------------------------------------------------------------

Although MYC functions in cancer metabolism are widely recognized, MYC is generally considered 'undruggable' largely due to its nuclear localization, lack of an enzymatic 'active site', and indispensable roles during normal development ([@bib54]). Hence, limited therapeutic strategies have been developed, and identification of the 'druggable' regulatory proteins of MYC becomes critical.

Our study reveals two modes of dysregulation of endogenous dMyc specifically during Hipk-induced tumorigenesis. The first mode is transcriptional stimulation of dMyc likely as a consequence of convergence of multiple signaling outputs ([Figures 3](#fig3){ref-type="fig"}--[4](#fig4){ref-type="fig"}). In our previous study, we found that genetically targeting individual signaling cascades failed to restrain Hipk tumor growth ([@bib4]). This is likely due to the redundancy of signaling cascades in inducing *dMyc* upregulation. It is also interesting to note that dMyc upregulation and the associated tumor growth are most striking in the wing hinge ([Figures 3](#fig3){ref-type="fig"}--[4](#fig4){ref-type="fig"}). The pouch region, however, seems more refractory to such alterations. We also observed the lowest intracellular glucose levels ([Figure 1g--h](#fig1){ref-type="fig"}) and robust *Ldh* upregulation ([Figure 2d](#fig2){ref-type="fig"}) in the hinge area. dMyc-dependent glucose uptake ([Figure 5b--c](#fig5){ref-type="fig"}), on the other hand, was enhanced in both hinge and pouch regions even though dMyc protein buildup is undetectable in the wing pouch, suggesting that glucose uptake is particularly sensitive to changes in dMyc levels. Our data therefore imply that the Warburg effect and the tumor growth phenotype may be linked to the dMyc levels being induced. The region-specific susceptibility to tumorigenic stimuli has been previously described and the hinge region was coined a 'tumor hotspot' because of its unique epithelial cell architectures and high endogenous JAK/STAT signaling ([@bib57]). It is possible that such features in the hinge region also contribute to the sensitivity of dMyc upregulation by elevated Hipk and other signaling pathways. Further studies are required to verify this proposition.

The second mode of dMyc regulation is the metabolic control of dMyc protein levels by aerobic glycolysis. Specifically, we found that the rate-limiting enzymes Pfk2 and Pfk are required to perpetuate dMyc buildup in tumor cells in a post-transcriptional manner ([Figure 6](#fig6){ref-type="fig"}). Similar to the effects on tumor growth, while *pfk2/pfk* knockdown prevented dMyc accumulation, knockdown of other glycolytic enzymes had little effect on sustaining dMyc accumulation. Such a disparity could possibly be explained by the potency of the glycolytic enzymes in controlling glycolytic flux. While Pfk2 and Pfk govern the rate-limiting, committed step of glycolysis, RNAi targeting other glycolytic genes may fail to render the corresponding steps rate-limiting, especially in tumors with elevated aerobic glycolysis. In other words, knockdown of other glycolytic enzymes may not reach the threshold that would restrict glycolytic flux as potently as *pfk2/pfk* knockdown. Given that Pfk2 is mis-expressed in tumor cells but not in normal cells ([Figure 2a](#fig2){ref-type="fig"}) and that dMyc accumulation is most sensitive to the Pfk2-Pfk mediated committed step of glycolysis specifically in tumor cells ([Figure 6](#fig6){ref-type="fig"}), targeting Pfk2 may be a favorable, selective metabolic strategy in the treatment of cancers, especially those displaying ectopic MYC expression.

Potential pro-tumorigenic roles of the pfk and Pfk2 in addition to their core biochemical role in glycolysis {#s3-3}
------------------------------------------------------------------------------------------------------------

The human homologs of fly Pfk and Pfk2 are PFK and PFK-2/FBPase (PFKFB), respectively. The functions of mammalian PFK and PFKFB in controlling glycolytic flux are well-defined. The allosteric regulation of PFK by F2,6-BP seems to be conserved among mammals and insects as F2,6-BP is able to activate insect Pfk, likely due to the conserved amino acid residues for F2,6-BP binding ([@bib44]). This suggests that Pfk2 can induce Pfk activation and hence glycolytic flux through biosynthesizing F2,6-BP. A previous report shows that flies lacking *pfk2* exhibited levels of circulating glucose and reduced sugar tolerance, providing a functional link between Pfk2 and glucose metabolism ([@bib25]). We provide evidence that both *pfk2* and *pfk* knockdown larvae exhibited significant decreases in pyruvate contents, confirming a conserved role of Pfk2 in regulating glycolytic flux.

Recently, the roles of PFK and PFKFB in the regulation of transcription factors or cofactors have drawn considerable attention. For example, vertebrate PFK was shown to physically interact with TEAD factors to stimulate YAP/TAZ activity, thus promoting proliferation and malignancy in cancer cells ([@bib17]). PFKFB4 (an isoform of PFK2) phosphorylates and activates oncogenic SRC-3 to promote breast cancers through stimulating purine synthesis ([@bib11]). These studies point to the fact that PFK and PFKFB functions are not restricted to metabolic regulation. Thus, it is tempting to speculate that Pfk2/Pfk may sustain ectopic dMyc through a direct interaction with or even phosphorylation of dMyc. That being said, as knockdown of Pfk2 or Pfk had no effects on dMyc protein levels under normal conditions ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}), we tend to believe that a tumorigenic environment with active aerobic glycolysis is necessary for the metabolic control of dMyc in particular through the committed step governed by Pfk2/Pfk. In summary, we and others show that glycolytic enzymes Pfk and Pfk2, likely through their core biochemical role in stimulating glycolytic flux, glycolysis-independent actions or both, act as key players in coupling metabolic demands with growth signals to achieve cancer progression.

Materials and methods {#s4}
=====================

*Drosophila* genetics {#s4-1}
---------------------

*Drosophila melanogaster* flies were raised on standard cornmeal-molasses food. Stocks were kept at 25°C and crosses at 29°C unless otherwise indicated. Three Gal4 fly lines, (1) *dpp-Gal4/TM6B*, (2) *hh-Gal4/TM6B* and (3) *act5c-Gal4/TM6B* (BL \#3954) were used to induce transgene expression. To generate heat-shock inducible actin flip-out clones, (4) *yw,hsFlp\[122\];;act\>CD2\>Gal4, UAS-RFP/TM6B* was used. To mark the transgene-expressing cells, (5) *UAS-GFP* (BL \#5431) and (6) *UAS-RFP* (BL \#7118) were used. To generate the Hipk tumor model, (7) *UAS-HA-hipk-3M* (abbreviated as *UAS-hipk*) ([@bib56]) and (8) *dpp-Gal4, UAS-hipk/TM6B* were used. RNAi fly strains used include (9) *UAS-dMyc-RNAi* (BL \#25783), (10) *UAS-dMyc-RNAi \#2* (BL \#25784), (11) *UAS-glut1-RNAi* (BL \#40904), (12) *UAS-hex-A-RNAi* (BL \#35155), (13) *UAS-hex-C-RNAi* (BL \#57404), (14) *UAS-pfk2-RNAi* (BL \#35380), (15) *UAS-pfk-RNAi* (BL \#34336), (16) *UAS-Ldh-RNAi* (BL \#33640), (17) *UAS-pgi-RNAi* (BL \#51804), (18) *UAS-pgk-RNAi* (BL \#33632) and (19) *UAS-pyk-RNAi* (BL \#35218). To perturb signaling pathway activities, the following strains were used: (20) *UAS-yki-S168A-GFP* (BL \#28836), (21) *UAS-Arm-S10* ([@bib42]), (22) *UAS-Ci-5M*, (23) *UAS-N-act*. Other strains used include (24) *myc-lacZ/FM7c* (BL \#12247) and (25) *UAS-dMyc* (BL \#9674). (26) *UAS-FLII12Pglu-700µδ6* (Glucose sensor) is a generous gift from Dr. Stefanie Schirmeier ([@bib64]). (27) *Ldh-GFP* is a generous gift from Dr. Ingrid Lohmann. Strains with BL stock number were obtained from Bloomington *Drosophila* Stock Center (Bloomington, IN, USA).

Flip-out clones {#s4-2}
---------------

A 10--15 min heat shock (37°C) was applied to larvae grown for two to three days after egg laying (25°C). After heat shock, the larvae were grown at 29°C and dissected when they reached third instar larval stage.

Immunofluorescence microscopy {#s4-3}
-----------------------------

Larval imaginal discs were dissected in PBS and fixed in 4% paraformaldehyde (PFA) for 15 min at room temperature. Samples were washed with PBS with 0.1% Triton X-100 (PBST). After blocking with 5% BSA in PBST for 1 hr at room temperature, samples were incubated with primary antibodies overnight at 4°C. The following primary antibodies were used: (1) mouse anti-β-Galactosidase (1:50, DSHB 40-1a), (2) rabbit anti-dMyc (d1-717) (1:500, Santa Cruz Biotechnology, Inc sc-28207), (3) rabbit anti-Hipk (1:200; [@bib4]), (4) mouse anti-Armadillo (1:50, diluted form, DSHB N2 7A1), (5) rabbit anti-Cyclin E (d-300) (1:100, Santa Cruz Biotechnology, Inc sc-33748). After washing with PBST, samples were incubated with Cy3- and/or Alexa Fluor 647-conjugated secondary antibodies (1:500, Jackson ImmunoResearch Laboratories, Inc), DAPI (4\',6-Diamidino-2-Phenylindole, Dihydrochloride) (final concentration: 0.2 μg per mL, Invitrogen D1306) and/or Rhodamine phalloidin (1:500, Molecular Probes R415) for 2 hr at room temperature. Samples were mounted in 70% Glycerol/PBS after wash. Images were taken on a Nikon Air laser-scanning confocal microscope and processed by Image J.

Quantitative RT-PCR (qRT-PCR) {#s4-4}
-----------------------------

Imaginal discs from third instar larva were dissected in PBS and temporarily stored in RNAlater Stabilization solution (Invitrogen AM7020). Total RNA was extracted using RNeasy Mini Kits (Qiagen 74101). First strand cDNA was synthesized using OneScript Plus cDNA Synthesis Kit (Abm G236). qRT-PCR were performed using SensiFast SYBR Hi-ROS Kit (Bioline 92005) on StepOne Real-time PCR System (Applied Biosystems).

2-NBDG uptake {#s4-5}
-------------

Imaginal discs from third instar larva were dissected in PBS, followed by incubation with 2-NBDG (Invitrogen N13195) at 0.3 mM for 15 min in the dark at room temperature. After rinsing with PBS, samples were fixed and processed according to standard immunofluorescence staining protocol.

Intracellular glucose FRET analysis {#s4-6}
-----------------------------------

The glucose sensor *UAS-FLII^12^Pglu-700µδ6* was generated by Dr. Schirmeier's group ([@bib64]). Imaginal discs expressing the sensor with or without overexpression of *hipk* were mounted and imaged on the same day. The same confocal settings as previously described ([@bib64]) were used to record the CFP and FRET images. FRET efficiency (FRET/CFP) was calculated as quotient of FRET and CFP using Image J. Since we were not determining the actual values of intracellular glucose concentrations, we did not take into account a correction for spectral bleed through and thus uncorrected FRET/CFP ratios were used to compare glucose levels in discs of different genotypes. The values of FRET efficiency were displayed using the Fire Lookup Table (LUT) in figures and shown in boxplots.

Pyruvate measurement {#s4-7}
--------------------

Whole-body larvae were homogenized in PBS, followed by centrifugation at 14,000 g for 10 min. The supernatants were used for the pyruvate assay. The pyruvate assay was performed using EnzyChrom Pyruvate Assay Kit (BioAssay Systems EPYR-100) according to the manufacturer's instructions. Absorbance at 570 nm was measured in a SpectraMax M5 fluorescent microplate reader (Molecular Devices). Relative pyruvate levels were determined after normalizing with the protein levels. Protein quantification was performed using the Bio-Rad protein assay (Bio-Rad 500--0006) and absorbance at 595 nm was measured. Experiments were conducted with two biological replicates. Each assay was performed with two technical replicates.

Statistics {#s4-8}
----------

For data analyses, unpaired two-tailed Student t-tests were used to determine *p*-values using Microsoft Excel. Bar graphs were generated by Microsoft Excel. Boxplots were generated using BoxPlotR with data points included ([@bib55]). We used the Spear definition to show the maximum and minimum values by the upper and lower whiskers, respectively. The third quartile, median and the first quartile are shown in the box accordingly to a standard boxplot.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Metabolic alterations involving a dMyc-Pfk2-Pfk regulatory loop and active mitochondrial metabolism drive tumor growth\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Jason Tennessen as the guest Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Utpal Banerjee as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The consensus view is that the manuscript provides an interesting description of a mechanism linking Hipk with aerobic glycolysis and mitochondrial metabolism within *Drosophila* larval cells. The manuscript provides three important observations:

1\) Hipk overexpression within the wing imaginal disc induces elevated glycolytic metabolism as determined by 2-NBDG uptake, a glucose FRET-sensor, and changes in gene expression related to glycolysis. Overall, these findings suggest that Hipk overexpression induces the Warburg effect in the wing disc.

2\) Hipk overexpression within the larval salivary glands induces significant changes in mitochondrial morphology and membrane potential.

3\) Loss of either Pfk or Pfk2 expression results in a decreased dMyc levels, hinting at a mechanism in which Hipk induced expression of Pfk and Pfk2 promotes dMyc accumulation.

Individually, each of these points is interesting, however, the studies of mitochondrial metabolism are largely conducted in the salivary gland while the glycolytic studies primarily take place within the wing imaginal disc. Combining these two tissue-specific studies into a single manuscript raises the question as to whether Hipk activates different metabolic programs within each tissue. This dilemma is further emphasized by the last paragraph of the Results section, which revealed that PFK2 but not PFK is required for mitochondrial elongation and branching phenotypes observed in the salivary glands. Since this result is in contrast to the Hipk-induced imaginal disc tumors, which are dependent on both PFK and PFK2, substantial effort would be required to understand how Hipk differentially regulates metabolism in these two tissues.

After several discussions, the reviewers agree that the strength of this study lies in the relationship between Hipk, dMyc, and Pfk/Pfk2 within the wing imaginal disc. The mechanism proposed by the wing disc studies are better defined than the salivary gland work and they reflect the heart of the manuscript. Based on this conclusion, the manuscript should be split in two, with the wing disc studies serving as the foundation of a major revision and the mitochondrial studies acting as seed for a future manuscript.

Essential revisions:

The reviewers agree that the following major revisions are required before the paper can be accepted at *eLife*:

1\) Reorganize the manuscript to focus on the link between Hipk, Myc, and glycolysis in the imaginal disc while removing the mitochondrial studies in the salivary gland.

2\) The reviewers request three additional sets of experiments to demonstrate that glycolysis is both elevated and necessary in HIPK-induced tumors.

i\) The reviewers would like additional experiments demonstrating that 2-NBDG serves as an accurate readout of cellular glucose import:

How efficient is the UAS-Glut-RNAi used?

Is Glut1 over-expression sufficient to cause an accumulation in 2-NBDG?

Does Glut1 depletion rescue tumor formation?

ii\) Please provide some evidence that Pfk2 activity is linked with increased glycolytic flux. Insect PFK is regulated differently than mammalian PFK, as the insect enzymes are insensitive to both citrate and AMP levels. This evidence could be provided by an appropriate set of references from the insect metabolism literature, a biochemical study using S2 cells, or measurements of lactate and pyruvate in larvae following whole body Pfk-2-RNAi.

iii\) The reviewers are concerned that the link between Pfk/Pfk2 and dMyc might not be the result of a direct interaction, but instead reflects a feedback from glycolysis onto dMyc stability. They request that the authors use RNAi to determine if depletion of other glycolytic enzymes affects Myc levels. Specifically, the authors should determine if dMyc levels are sensitive to the loss of a glycolytic enzyme that is encoded by a single gene (unlike the hexokinases) and directly catalyzes a glycolytic reaction (unlike Ldh). Possible suggestions would be Pgi, Pyk, or Pgk.

3\) The authors must strengthen the connection between HIPK up-regulation and dMyc expression.

i\) The authors claim in Figure 4 that HIPK induces elevated dMyc levels. While the increase in dMyc-lacZ resembles the dpp-expression pattern, dMyc protein levels exhibit a different pattern. The authors should clarify this discrepancy. Moreover, dMyc protein levels appear to be increased in some regions of the disc but not in all the dpp-expressing cells (e.g., the wing pouch in Figure 4E, or Figure 6A). The use of clones over-expressing Hipk could help the authors to assess this potential region specificity in dMyc protein upregulation.

ii\) There are also concerns regarding the section that examines the role of different signaling pathways on dMyc protein levels. The authors examine dMyc protein when different pathways are deregulated in the disc but do not evaluate the effect of dMyc expression. The use of clones might give better resolution and will allow showing these results in a clearer manner.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A dMyc-Pfk2-Pfk regulatory loop drives the Warburg effect and tumor growth\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Utpal Banerjee (Senior Editor), a Reviewing Editor, and three reviewers.

The manuscript has been substantially improved but there are a few remaining issues that need to be addressed before acceptance. As outlined by reviewer 3 and mentioned in my comments (reviewer 1), there are still concerns regarding the conclusion that PfK and Pfk2 promote dMyc stability independent of glycolytic flux. I would ask that you address these concerns within the text. In particular, please discuss alternative models that could explain your observations and justify why you favor a glycolysis-independent role for Pfk and Pfk2.

*Reviewer \#1:*

The revised manuscript Wong, Lio, and Verheyen is significantly improved and all of my major concerns have been addressed. I have two minor revisions that the authors should address prior to publication.

1\) In subsection "Aerobic glycolysis (the Warburg effect) is essential to tumor growth through sustaining ectopic dMyc expression", the statement that glycolysis is indispensable for *Drosophila* growth and development needs some citations. Also, the authors should revise the sentence to state that glycolysis is indispensable for larval development....Pfk mutants can survive until L2 and therefore survive embryogenesis. While this is likely due to maternal loading of the enzyme, the authors should use a more nuanced statement to start this section.

2\) The glycolytic studies are significantly improved. But the authors can\'t rule out the possibility that RNAi targeting the other genes, such as Pgk and Pgi, fails to lower enzyme activity below a level that would restrict glycolytic flux. A brief qualifying statement about this in the discussion would alleviate my concerns.

*Reviewer \#2:*

In the revised version of their manuscript, the authors have addressed all my concerns and, in my view, it is ready for publication.

*Reviewer \#3:*

The manuscript is improved following the omission of the salivary gland data. The focus on the wing disc eliminates the confusion caused by studying the divergent phenotypes in the different tissues.

Much of the manuscript now discusses the role of glycolysis in tumor growth. The authors were asked to provide additional data to bolster the assertion that Hipk over-expression causes glycolysis to be increased and that the increase in glycolysis is necessary. Particularly, the authors were also asked to demonstrate that the stability of dMyc was due to a direct interaction between Pfk/Pfk2 and dMyc.

While the authors performed many of the experiments requested, it is still not clear if the changes in tumor growth and dMyc stability are due to a direct interaction between Pfk or Pfk2 with dMyc (i.e. a mechanism that does not involve glycolysis) or whether the glycolytic role of Pfk is critical, but glycolysis is especially sensitive to inhibition at the Pfk step. In the rebuttal, the authors propose that the direct interaction model is supported by negative data describing the relative unimportance of the other glycolytic steps. The authors performed RNAi knock-downs of the other glycolytic enzymes (as requested during the initial review). These experiments show that knock-down of the other glycolytic enzymes do not reduce dMyc stability, but have also only, surprisingly, a very minor impact on tumor growth (Figure 6---figure supplement 1, Figure 6---figure supplement 2, Figure 6---figure supplement 3, Figure 6---figure supplement 4 and Figure 6---figure supplement 5). Is it really true, then, that elevated glucose import or glycolysis is not necessary for tumor growth, or could it be that the knock-downs of the other glycolytic enzymes do not reduce glycolytic flux to the same extent as the Pfk/Pfk2 knock-down? This is a very difficult question to resolve without quantitative flux data, though accepting the conclusion that elevated glycolysis is not necessary for tumor growth would be contrary to much previous work. The other solution to distinguishing between the two models would be to provide a clear mechanistic model that describes how Pfk/Pfk2 promotes dMyc stability independent of the role of Pfk in glycolysis -- the authors provide no new data to describe how such a mechanism might operate.

In the absence of new data, I don\'t think a glycolysis-independent role of Pfk is supported -- right now it seems very difficult to separate the two phenomena. Any model that is proposed should take this uncertainty more fully into account. On the other hand, it seems very reasonable to say the targeted inhibition of glycolysis is necessary to reduce tumor-growth and that the Pfk/Pfk2 step is the most sensitive step in this system (e.g. subsection "dMyc-driven metabolic rewiring in Hipk tumor model").

10.7554/eLife.46315.026

Author response

> Essential revisions:
>
> The reviewers agree that the following major revisions are required before the paper can be accepted at eLife:
>
> 1\) Reorganize the manuscript to focus on the link between Hipk, Myc, and glycolysis in the imaginal disc while removing the mitochondrial studies in the salivary gland.

Our manuscript now focuses on the link the between Hipk tumor growth, dMyc upregulation and the Warburg effect in the wing imaginal discs.

> 2\) The reviewers request three additional sets of experiments to demonstrate that glycolysis is both elevated and necessary in HIPK-induced tumors.
>
> i\) The reviewers would like additional experiments demonstrating that 2-NBDG serves as an accurate readout of cellular glucose import:
>
> How efficient is the UAS-Glut-RNAi used?

The knockdown efficiency of the *UAS-glut1-RNAi* was evaluated by qRT-PCR. We found that expression of *glut1-RNAi* led to a \~70% decrease in *glut1* mRNA expression. Other RNAi lines used in this study to silence glycolytic genes were also tested. These data are shown in Figure 1 ---figure supplement 2.

> Is Glut1 over-expression sufficient to cause an accumulation in 2-NBDG?

It has been shown that expression of *glut1* is sufficient to increase cellular uptake of 2-NBDG (Niccoli et al.,2016), demonstrating that 2-NBDG is a valid tool to monitor glucose uptake in *Drosophila*. Additional examples of using 2-NBDG in *Drosophila* are provided in the manuscript. This information is included in the second paragraph of the Results section.

> Does Glut1 depletion rescue tumor formation?

We found that depletion of *glut1* failed to rescue Hipk tumor growth (Figure 6---figure supplement 3) despite our results showing that knockdown of *glut1* moderately reduces glucose transport in the tumor cells. We also checked the tumor growth when we knocked down those glycolytic enzymes without genetic redundancy. Depletion of Pgk, Pyk or Ldh at most slightly reduced tumor growth, whereas Pfk or Pfk2 knockdown blocked tumor growth. This implies that whereas aerobic glycolysis might partly fuel overgrowth, targeted but not generic inhibition of glycolysis is required to abrogate tumor growth. See more in the section below -- 2 iii.

> ii\) Please provide some evidence that Pfk2 activity is linked with increased glycolytic flux. Insect PFK is regulated differently than mammalian PFK, as the insect enzymes are insensitive to both citrate and AMP levels. This evidence could be provided by an appropriate set of references from the insect metabolism literature, a biochemical study using S2 cells, or measurements of lactate and pyruvate in larvae following whole body Pfk-2-RNAi.

Nunes et al.,(2016) reported that unlike mammalian PFK, PFK from insects (*A. aegypti*) is insensitive to citrate or AMP likely due to the non-conserved amino acid sequences for citrate and AMP binding sites. Interestingly, in the study, the authors found that F2,6-BP is able to activate insect PFK, suggesting that the regulation of PFK by F2,6-BP is conserved among mammals and insects. Indeed, the amino acid residues involved in F2,6-BP binding in PFK are conserved among mammals and insects including *Drosophila*.

The roles of Pfk2 in *Drosophila* are less studied. We only found one study showing that flies depleted of Pfk2 exhibit elevated levels of circulating glucose and reduced sugar tolerance (Havula et al., 2013). In our study, we found that knockdown of *pfk2* mimics the effects of knockdown of other key glycolytic genes, causing lethality in flies. Also, *pfk2* knockdown phenocopies the effect of *pfk* knockdown, leading to decreases in pyruvate levels in flies (Figure 6---figure supplement 1).

All these pieces of evidence illustrate the importance of fly Pfk2 in controlling glycolytic flux.

> iii\) The reviewers are concerned that the link between Pfk/Pfk2 and dMyc might not be the result of a direct interaction, but instead reflects a feedback from glycolysis onto dMyc stability. They request that the authors use RNAi to determine if depletion of other glycolytic enzymes affects Myc levels. Specifically, the authors should determine if dMyc levels are sensitive to the loss of a glycolytic enzyme that is encoded by a single gene (unlike the hexokinases) and directly catalyzes a glycolytic reaction (unlike Ldh). Possible suggestions would be Pgi, Pyk, or Pgk.

To address whether elevated glycolytic activities contribute to the maintenance of dMyc expression, we used RNAi to knockdown *glut1, pgi, pyk* and *pgk*. Unlike *pfk2/pfk* knockdown, we found that none of the knockdowns suppressed dMyc upregulation (Figure 6---figure supplement 3), suggesting that loss of dMyc in *pfk2/pfk* knockdown is not due to attenuation of glycolytic flux.

> 3\) The authors must strengthen the connection between HIPK up-regulation and dMyc expression.
>
> i\) The authors claim in Figure 4 that HIPK induces elevated dMyc levels. While the increase in dMyc-lacZ resembles the dpp-expression pattern, dMyc protein levels exhibit a different pattern. The authors should clarify this discrepancy. Moreover, dMyc protein levels appear to be increased in some regions of the disc but not in all the dpp-expressing cells (e.g., the wing pouch in Figure 4E, or Figure 6A). The use of clones over-expressing Hipk could help the authors to assess this potential region specificity in dMyc protein upregulation.

We examined dMyc upregulation in *dpp\>hipk* discs where *hipk* was overexpressed along the anterior/posterior boundary. We observed that the increase in the β-gal signal appeared to be the largest in the presumptive wing hinge where the tumor cells proliferated most rapidly, while the intensity decreased when moving away from the hinge region. We detected accumulation of dMyc proteins in the wing hinge, which positively correlates with the marked increase in dMyc mRNA levels in the same area. On the other hand, dMyc protein levels remained unchanged in the wing pouch, possibly due to weak induction of dMyc transcription

> ii\) There are also concerns regarding the section that examines the role of different signaling pathways on dMyc protein levels. The authors examine dMyc protein when different pathways are deregulated in the disc but do not evaluate the effect of dMyc expression. The use of clones might give better resolution and will allow showing these results in a clearer manner.

Using the strategy mentioned above, we used clones to examine the roles of different signaling pathways on dMyc expression. Similar to elevated Hipk, we observed that perturbations in the tested signaling cascades cause ectopic dMyc expression specifically in the wing hinge but not in the pouch region. Data are shown in Figure 4 and Figure 4---figure supplement 1. We discussed such dichotomy in the Discussion section.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been substantially improved but there are a few remaining issues that need to be addressed before acceptance. As outlined by reviewer 3 and mentioned in my comments (reviewer 1), there are still concerns regarding the conclusion that PfK and Pfk2 promote dMyc stability independent of glycolytic flux. I would ask that you address these concerns within the text. In particular, please discuss alternative models that could explain your observations and justify why you favor a glycolysis-independent role for Pfk and Pfk2.

We thank the editors and reviewers for their thoughtful and constructive feedback to our revised manuscript. We believe that in this edited version, we have addressed the concerns and discussed broader interpretations, and we hope the reviewers agree.

Given that inhibition of Pfk2 and Pfk potently rescues dMyc accumulation and the associated tumor growth in our Hipk tumor model, we previously focused on the potential links between the Pfk2-Pfk axis and dMyc, which could be therapeutically valuable in cancer treatment. We agree with reviewers that the suppression effect could be explained by two alternative models, a direct interaction between dMyc and Pfk2/Pfk and a general attenuation of glycolytic flux. In light of this, we changed the focus from the dMyc-Pfk2-Pfk interactions to emphasizing the feedback loop between dMyc and aerobic glycolysis, and correspondingly have changed the title to "A positive feedback loop between Myc and aerobic glycolysis sustains tumor growth in a *Drosophila* tumor model". Furthermore, we highlight that inhibition of the Pfk2/Pfk-governed committed step of glycolysis may serve as an effective approach to abrogate tumor growth.

In the last paragraph of the Discussion section, we provide some references showing that in human cancer cells, PFK and PFKFB (Pfk2 in flies) can physically interact or directly phosphorylate oncogenic proteins like TEAD factors (Enzo et al.,2015) or SRC-3 (Dasgupta et al.,2018). Thus, it is tempting to speculate that Pfk2/Pfk may sustain ectopic dMyc through a direct interaction with or even phosphorylation of dMyc (subsection "Potential pro-tumorigenic roles of the Pfk and Pfk2 in addition to their core biochemical role in glycolysis"). However, we currently do not have appropriate reagents like fly strains or antibodies to investigate the potential physical interactions, and those studies are beyond the scope of the current study.

In summary, we and others show that glycolytic enzymes Pfk and Pfk2, likely through their core biochemical role in stimulating glycolytic flux, glycolysis-independent actions or both, act as key players in coupling metabolic demands with growth signals to achieve cancer progression. (subsection "Potential pro-tumorigenic roles of the Pfk and Pfk2 in addition to their core biochemical role in glycolysis")

> Reviewer \#1:
>
> The revised manuscript Wong, Lio, and Verheyen is significantly improved and all of my major concerns have been addressed. I have two minor revisions that the authors should address prior to publication.

*1) In subsection "Aerobic glycolysis (the Warburg effect) is essential to tumor growth through sustaining ectopic dMyc expression", the statement that glycolysis is indispensable for Drosophila growth and development needs some citations. Also, the authors should revise the sentence to state that glycolysis is indispensable for larval development....Pfk mutants can survive until L2 and therefore survive embryogenesis. While this is likely due to maternal loading of the enzyme, the authors should use a more nuanced statement to start this section.*

We have replaced the statement by 'Earlier studies have shown that flies incompetent at glycolysis displayed reduced viability'. We also refer to previous studies that showed that deletion or ubiquitous knockdown of glycolysis genes resulted in lethality in files, which are consistent with our knockdown analyses.

We also mention that the lethal phenotype could presumably be determined by maternal contribution, knockdown efficiency, or the importance of the glycolytic step which the particular enzyme controls.

> 2\) The glycolytic studies are significantly improved. But the authors can\'t rule out the possibility that RNAi targeting the other genes, such as Pgk and Pgi, fails to lower enzyme activity below a level that would restrict glycolytic flux. A brief qualifying statement about this in the discussion would alleviate my concerns.

We now provide the required statements when we discuss the different effects of Pfk2/Pfk knockdown or knockdown of other glycolytic genes on tumor growth and dMyc accumulation.

Reviewer \#3:

> \[...\] In the absence of new data, I don\'t think a glycolysis-independent role of Pfk is supported -- right now it seems very difficult to separate the two phenomena. Any model that is proposed should take this uncertainty more fully into account. On the other hand, it seems very reasonable to say the targeted inhibition of glycolysis is necessary to reduce tumor-growth and that the Pfk/Pfk2 step is the most sensitive step in this system (e.g. subsection "dMyc-driven metabolic rewiring in Hipk tumor model").

Some of these concerns have been addressed in our response to reviewer 1.

In addition, we are inclined to believe that aerobic glycolysis is crucial for tumor growth despite a potential direct interaction between dMyc and Pfk2/Pfk. We found that knockdown of Pfk2 or Pfk had no effects on dMyc protein levels under normal conditions (Figure 6---figure supplement 4). This suggests that a tumorigenic environment with active aerobic glycolysis is essential for the metabolic control of dMyc in particular through the committed step governed by Pfk2/Pfk. (subsection "Potential pro-tumorigenic roles of the Pfk and Pfk2 in addition to their core biochemical role in glycolysis).
